Phytochemicals as adjunctive with conventional anticancer therapies

Current Pharmaceutical Design

Volumn 22, Issue 27, 2016, Pages 4201-4218

  Farzaei, Mohammad Hosein ^a,b   Bahramsoltani, Roodabeh ^c   Rahimi, Roja ^d  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antineoplastic; Cancer; Chemotherapeutic; Herbal compound; Medicinal plant; Natural product; Neoplasia; Phytochemical; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; AVISCUMINE; BETA CAROTENE; BOSWELLIC ACID; CANNABINOID; COUMARIN; CURCUMIN; DIINDOLYLMETHANE; ELLAGIC ACID; EPIGALLOCATECHINGALLATE; GAMBOGIC ACID; GENISTEIN; GINSENOSIDE; GOSSYPOL; HOMOHARRINGTONINE; LYCOPENE; PERILLYL ALCOHOL; PLANT MEDICINAL PRODUCT; RESVERATROL; SALIDROSIDE; SCHIZOPHYLLAN; SILIBININ; TROXERUTIN; UNCLASSIFIED DRUG; VITEXIN;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; COCHRANE LIBRARY; DIGESTIVE SYSTEM CANCER; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MEDLINE; MULTICENTER STUDY (TOPIC); NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; ADJUVANT CHEMOTHERAPY; CHEMISTRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASMS; PHYTOCHEMICALS;

EID: 84986910246     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160601100823     Document Type: Review

References (91)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Cancer. Fact Sheet No. 2971. Geneva, Switzerland: World Health Organization 2014.
3. Nussbaumer S, Bonnabry P, Veuthey JL, et al. Analysis of anticancer drugs: a review. Talanta 2011; 85: 2265-89.
4. Liang XJ, Chen C, Zhao Y, et al. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010; 596: 467-88.
5. Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol 2010; 263: 179-88.
6. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 2004; 134: 3479S-85S.
7. Rahimi R, Taheripanah T, Rezaeizadeh H. An evidence based approach to traditional herbal remedies for the management of cancer. In: Saeidnia S, Ed. New Approaches to Natural Anticancer Drugs. USA: Springer International Publishing 2015.
8. da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol 2001; 1: 364-9.
9. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007; 9: 767-76.
10. Azimi H, Khakshur AA, Abdollahi M, et al. Potential new pharmacological agents derived from medicinal plants for the treatment of pancreatic cancer. Pancreas 2015; 44: 11-15.
11. Giacoppo S, Mandolino G, Galuppo M, et al. Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 2014; 19: 18781-816.
12. Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795-7.
13. Ungerleider JT, Andrysiak T, Fairbanks L, et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 1982; 50: 636-45.
14. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-400.
15. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Sympt Manage 2010; 39: 167-79.
16. Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Sympt Manage 2013; 46: 207-18.
17. Beck-Steiner G. Influencing of xerostomia and asialia during psychotropic drug therapy with benzopyrone. Munch Med Wochenschr 1979; 121: 569-70.
18. Grotz KA, Wustenberg P, Kohnen R, et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective, randomized, placebocontrolled, double-blind study. Br J Oral Maxillofac Surg 2001; 39: 34-9.
19. Peret-Almeida L, Cherubino APF, Alves RJ, et al. Separation and determination of the physico-chemical characteristics of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Res Int 2005; 38: 1039-44.
20. Belcaro G, Hosoi M, Pellegrini L, et al. A controlled study of a lecithinized delivery system of curcumin (MerivaR) to alleviate the adverse effects of cancer treatment. Phytother Res 2014; 28: 444-50.
21. Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res 2013; 180: 34-43.
22. Panahi Y, Saadat A, Beiraghdar F, et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-7.
23. Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets. CNS Neurosci Ther 2011; 17: 761-8.
24. Bahramsoltani R, Farzaei MH, Farahani MS, et al. Phytochemical constituents as future antidepressants: a comprehensive review. Rev Neurosci 2015; 26: 699-719.
25. Niranjana Murthy H, Dandin VS, YoeupPaek K. Hepatoprotective activity of ginsenosides from Panax ginseng adventitious roots against carbon tetrachloride treated hepatic injury in rats. J Ethnopharmacol 2014; 158 Pt A: 442-6.
26. Yinglu F, Changquan L, Xiaofeng Z, et al. A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization. J Altern Complement Med 2009; 15: 175-81.
27. Lu P, Su W, Miao ZH, et al. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 2008; 14: 33-6.
28. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J Agric Food Chem 2002; 50: 565-70.
29. Zhao H, Zhu W, Xie P, et al. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III nonsmall-cell lung cancer. Radiother Oncol 2014; 110: 132-6.
30. Lin SS, Hung CF, Tyan YS, et al. Ellagic acid inhibits arylamine Nacetyltransferase activity and DNA adduct formation in human bladder tumor cell lines (T24 and TSGH 8301). Urol Res 2001; 29: 371-6.
31. Falsaperla M, Morgia G, Tartarone A, et al. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 2005; 47: 449-54; discussion 454-5.
32. Hien TV, Huong NB, Hung PM, et al. Radioprotective effects of vitexina for breast cancer patients undergoing radiotherapy with cobalt-60. Integr Cancer Ther 2002; 1: 38-4; discussion 42-3.
33. Wu T, Zhou H, Jin Z, et al. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. Eur J Pharmacol 2009; 613: 93-9.
34. Zhang H, Shen WS, Gao CH, et al. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R D 2012; 12: 101-6.
35. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010; 9: 8-14.
36. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120-5.
37. He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011; 29: 208-13.
38. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
39. Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137-41.
40. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-64.
41. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013; 71: 1521-30.
42. Palozza P, Catalano A, Simone R, et al. Lycopene as a guardian of redox signalling. Acta Biochim Pol 2012; 59: 21-5.
43. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomyvsorchidectomy alone in the management of advanced prostate cancer. BJU Int 2003; 92: 375-8; discussion 378. Erratum in: BJU Int 2004; 93: 655.
44. Barber NJ, Zhang X, Zhu G, et al. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis 2006; 9: 407-13.
45. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001; 10: 861-8.
46. Schwenke C, Ubrig B, Thurmann P, et al. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. J Urol 2009; 181: 1098-103.
47. Zhang X, Yang Y, Wang Q. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. Chin Med J (Engl) 2014; 127: 2143-6.
48. Magbanua MJ, Roy R, Sosa EV, et al. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One 2011; 6: e24004.
49. Mariani S, Lionetto L, Cavallari M, et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci 2014; 15: 1433-40.
50. Bunker CH, McDonald AC, Evans RW, et al. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer 2007; 57: 130-7.
51. Gontero P, Marra G, Soria F, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"? Prostate 2015; 75: 1177-86.
52. Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 149-57.
53. Azzoli CG, Miller VA, Ng KK, et al. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 2003; 51: 493-8.
54. Matos JM, Schmidt CM, Thomas HJ, et al. A pilot study of perillyl alcohol in pancreatic cancer. J Surg Res 2008; 147: 194-9.
55. Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003; 21: 367-72.
56. Ripple GH, Gould MN, Stewart JA, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998; 4: 1159-64.
57. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25: 139-46.
58. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010; 70: 848-55.
59. O’Dwyer PJ, King SA, Hoth DF, et al. Homoharringtonine--perspectives on an active new natural product. J Clin Oncol 1986; 4: 1563-8.
60. Bell BA, Chang MN, Weinstein HJ. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol 2001; 37: 103-7.
61. O’Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149-53.
62. Mockel B, Schwarz T, Zinke H, et al. Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines. Arzneimittelforschung 1997; 47: 1145-51.
63. Schoffski P, Riggert S, Fumoleau P, et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the european organization for research and treatment of cancer new drug development Group. Ann Oncol 2004; 15: 1816-24.
64. Schaffrath B, Mengs U, Schwarz T, et al. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res 2001; 21: 3981-7.
65. Bergmann L, Aamdal S, Marreaud S, et al. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer 2008; 44: 1657-62.
66. Schoffski P, Breidenbach I, Krauter J, et al. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer 2005; 41: 1431-8.
67. Ziegler RG. A review of epidemiologic evidence that carotenoids reduce the risk of cancer. J Nutr 1989; 119: 116-22.
68. Kazi N, Radvany R, Oldham T, et al. Immunomodulatory effect of beta-carotene on T lymphocyte subsets in patients with resected colonic polyps and cancer. Nutr Cancer 1997; 28: 140-5.
69. Manetta A, Schubbert T, Chapman J, et al. beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Pre 1996; 5: 929-32.
70. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 2001; 61: 1457-63.
71. Toma S, Bonelli L, Sartoris A, et al. beta-carotene supplementation in patients radically treated for stage I-II head and neck cancer: results of a randomized trial. Oncol Rep 2003; 10: 1895-901.
72. Margalit DN, Kasperzyk JL, Martin NE, et al. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians’ Health Study. Int J Radiat Oncol Biol Phys 2012; 83: 28-32.
73. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010; 29: 465-82.
74. Messing E, Gee JR, Saltzstein DR, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) 2012; 5: 621-30.
75. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004; 48: 160-70.
76. Del Priore G, Gudipudi DK, Montemarano N, et al. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol 2010; 116: 464-7.
77. Yoneda K, Ueta E, Yamamoto T, et al. Immunoregulatory effects of sizofiran (SPG) on lymphocytes and polymorphonuclear leukocytes. Clin Exp Immunol 1991; 86: 229-35.
78. Miyazaki K, Mizutani H, Katabuchi H, et al. Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecol Oncol 1995; 56: 412-20.
79. Farzaei MH, Abdollahi M, Rahimi R. Role of dietary polyphenols in the management of peptic ulcer. World J Gastroenterol 2015; 21: 6499-517.
80. Sodagari HR, Farzaei MH, Bahramsoltani R, et al. Dietary anthocyanins as a complementary medicinal approach for management of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015; 9: 807-20.
81. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 2011; 4: 1419-25.
82. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392-9.
83. Farzaei MH, Farzaei F, Gooshe M, et al. Potentially effective natural drugs in treatment for the most common rheumatic disorder: osteoarthritis. Rheumatol Int 2015; 35: 799-814.
84. Janssen G, Bode U, Breu H, et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr 2000; 212: 189-95.
85. Coyle T, Levante S, Shetler M, et al. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol 1994; 19: 25-35.
86. Bushunow P, Reidenberg MM, Wasenko J, et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 1999; 43: 79-86.
87. Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappa B signaling pathway. Blood 2007; 110: 3517-25.
88. Chi Y, Zhan XK, Yu H, et al. An open-labeled, randomized, multicenter phase II a study of gambogic acid injection for advanced malignant tumors. Chin Med J (Engl) 2013; 126: 1642-6.
89. Shokoohinia Y, Hosseinzadeh L, Alipour M, et al. Comparative evaluation of cytotoxic and apoptogenic effects of several coumarins on human cancer cell lines: osthole induces apoptosis in p53-deficient H1299 cells. Adv Pharmacol Sci 2014; 2014: 847574.
90. Farahani MS, Bahramsoltani R, Farzaei MH, et al. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. Rev Neurosci 2015; 26: 305-21.
91. Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007; 59: 1-7.